{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:08:43Z","timestamp":1792372123356,"version":"4.4.0"},"reference-count":61,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)\u2013related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their posttreatment clone size. We enrolled a total of 449 patients with MDS or related myeloid neoplasms. They were analyzed for gene mutations in pretreatment (n\u00a0= 449) and posttreatment (n\u00a0= 289) bone marrow samples using targeted-capture sequencing to assess the impact of gene mutations and their posttreatment clone size on treatment outcomes. In Cox proportional hazard modeling, multihit TP53 mutation (hazard ratio [HR], 2.03; 95% confidence interval [CI], 1.42-2.91; P\u00a0&amp;lt; .001), EZH2 mutation (HR, 1.71; 95%\u00a0CI, 1.14-2.54; P\u00a0= .009), and DDX41 mutation (HR, 0.33; 95%\u00a0CI, 0.17-0.62; P\u00a0&amp;lt; .001), together with age, high-risk karyotypes, low platelets, and high blast counts, independently predicted OS. Posttreatment clone size accounting for all drivers significantly correlated with International Working Group (IWG) response (P\u00a0&amp;lt; .001, using trend test), except for that of DDX41-mutated clones, which did not predict IWG response. Combined, IWG response and posttreatment clone size further improved the prediction of the original model and even that of a recently proposed molecular prediction model, the molecular International Prognostic Scoring System (IPSS-M; c-index, 0.653 vs 0.688; P\u00a0&amp;lt; .001, using likelihood ratio test). In conclusion, evaluation of posttreatment clone size, together with the pretreatment mutational profile as well as the IWG response play a role in better prognostication of azacitidine-treated patients with myelodysplasia.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009564","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T17:20:10Z","timestamp":1680110410000},"page":"3624-3636","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms"],"prefix":"10.1182","volume":"7","author":[{"given":"Yasuhito","family":"Nannya","sequence":"first","affiliation":[{"name":"1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"},{"name":"2Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-5852","authenticated-orcid":false,"given":"Magnus","family":"Tobiasson","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"4Division of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan"},{"name":"6Japan Adult Leukemia Study Group, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2057-7187","authenticated-orcid":false,"given":"Elsa","family":"Bernard","sequence":"additional","affiliation":[{"name":"7Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0112-6564","authenticated-orcid":false,"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[{"name":"8Kanazawa University, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Takeda","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0871","authenticated-orcid":false,"given":"Maria","family":"Creignou","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"4Division of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-0699","authenticated-orcid":false,"given":"Lanying","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kusakabe","sequence":"additional","affiliation":[{"name":"9Department of Hematology, University of Tsukuba, Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-8903","authenticated-orcid":false,"given":"Yuhei","family":"Shibata","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Gifu Municipal Hospital, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-7777","authenticated-orcid":false,"given":"Nobuhiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"11Department of Hematology & Infectious Disease, Gifu University Hospital, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4030-4653","authenticated-orcid":false,"given":"Mizuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Oncology, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shiozawa","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"14Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"15Department of Integrated Data Science, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-5414","authenticated-orcid":false,"given":"Nobuyuki","family":"Kakiuchi","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Makishima","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6420-2555","authenticated-orcid":false,"given":"Masahiro","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-4470","authenticated-orcid":false,"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[{"name":"16Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Watanabe","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Japan Red Cross Osaka Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[{"name":"19Department of Hematology, Gunma University, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-5814","authenticated-orcid":false,"given":"Masataka","family":"Taguchi","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Sasebo City General Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2322-4798","authenticated-orcid":false,"given":"Toru","family":"Kiguchi","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Chugoku Central Hospital, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0845-5758","authenticated-orcid":false,"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-4284","authenticated-orcid":false,"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Oncology, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[{"name":"11Department of Hematology & Infectious Disease, Gifu University Hospital, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1784-2402","authenticated-orcid":false,"given":"Senji","family":"Kasahara","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Gifu Municipal Hospital, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7803-7338","authenticated-orcid":false,"given":"Shigeru","family":"Chiba","sequence":"additional","affiliation":[{"name":"9Department of Hematology, University of Tsukuba, Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[{"name":"6Japan Adult Leukemia Study Group, Japan"},{"name":"23Nagoya Medical Center, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-6616","authenticated-orcid":false,"given":"Satoru","family":"Miyano","sequence":"additional","affiliation":[{"name":"15Department of Integrated Data Science, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elli","family":"Papaemanuil","sequence":"additional","affiliation":[{"name":"7Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan"},{"name":"6Japan Adult Leukemia Study Group, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hellstr\u00f6m-Lindberg","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"4Division of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-5374","authenticated-orcid":false,"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"},{"name":"3Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden"},{"name":"24Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"issue":"10","key":"2023072115504747600_bib1","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023072115504747600_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1179\/1607845415Y.0000000039","article-title":"Treatment with 5-azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: a single center observational study","volume":"21","author":"Papageorgiou","year":"2016","journal-title":"Hematology"},{"issue":"3","key":"2023072115504747600_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"2023072115504747600_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"2023072115504747600_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2023072115504747600_bib6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/gcc.20877","article-title":"DNMT3B gene amplification predicts resistance to DNA demethylating drugs","volume":"50","author":"Simo-Riudalbas","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"2023072115504747600_bib7","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/leu.2011.170","article-title":"Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine","volume":"25","author":"Voso","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"2023072115504747600_bib8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/10428194.2011.651618","article-title":"Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents","volume":"53","author":"Itzykson","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2023072115504747600_bib9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk Res"},{"issue":"17","key":"2023072115504747600_bib10","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2023072115504747600_bib11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3109\/10428194.2013.855309","article-title":"Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents","volume":"55","author":"DiNardo","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023072115504747600_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2023072115504747600_bib13","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/leu.2015.314","article-title":"Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine","volume":"30","author":"Desoutter","year":"2016","journal-title":"Leukemia"},{"issue":"34","key":"2023072115504747600_bib14","doi-asserted-by":"crossref","first-page":"55264","DOI":"10.18632\/oncotarget.10526","article-title":"Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome","volume":"7","author":"Jung","year":"2016","journal-title":"Oncotarget"},{"key":"2023072115504747600_bib15","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"2023072115504747600_bib16","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.18632\/oncotarget.7290","article-title":"Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents","volume":"7","author":"Takahashi","year":"2016","journal-title":"Oncotarget"},{"issue":"16","key":"2023072115504747600_bib17","doi-asserted-by":"crossref","first-page":"22103","DOI":"10.18632\/oncotarget.7899","article-title":"Mutations in histone modulators are associated with prolonged survival during azacitidine therapy","volume":"7","author":"Tobiasson","year":"2016","journal-title":"Oncotarget"},{"issue":"63","key":"2023072115504747600_bib18","doi-asserted-by":"crossref","first-page":"106948","DOI":"10.18632\/oncotarget.22157","article-title":"Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes","volume":"8","author":"Cedena","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"2023072115504747600_bib19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00277-016-2912-7","article-title":"Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy","volume":"96","author":"Hiller","year":"2017","journal-title":"Ann Hematol"},{"issue":"3","key":"2023072115504747600_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","article-title":"Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes","volume":"20","author":"Unnikrishnan","year":"2017","journal-title":"Cell Rep"},{"issue":"12","key":"2023072115504747600_bib21","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"Dohner","year":"2018","journal-title":"Leukemia"},{"issue":"45","key":"2023072115504747600_bib22","doi-asserted-by":"crossref","first-page":"27882","DOI":"10.18632\/oncotarget.25328","article-title":"Efficacy of azacitidine is independent of molecular and clinical characteristics--an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature","volume":"9","author":"Kuendgen","year":"2018","journal-title":"Oncotarget"},{"issue":"11","key":"2023072115504747600_bib23","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00277-018-3464-9","article-title":"Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes","volume":"97","author":"Wang","year":"2018","journal-title":"Ann Hematol"},{"issue":"3","key":"2023072115504747600_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41375-018-0284-9","article-title":"Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes","volume":"33","author":"Falconi","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"2023072115504747600_bib25","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00277-019-03811-x","article-title":"Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"98","author":"Qin","year":"2019","journal-title":"Ann Hematol"},{"issue":"6","key":"2023072115504747600_bib26","first-page":"3651","article-title":"Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs","volume":"11","author":"Wu","year":"2019","journal-title":"Am J Transl Res"},{"issue":"3","key":"2023072115504747600_bib27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00277-020-03932-8","article-title":"Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine","volume":"99","author":"Martin","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"2023072115504747600_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2023072115504747600_bib29","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2023072115504747600_bib30","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023072115504747600_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-012-1565-4","article-title":"Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification","volume":"92","author":"Font","year":"2013","journal-title":"Ann Hematol"},{"issue":"21","key":"2023072115504747600_bib32","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023072115504747600_bib33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/leu.2016.282","article-title":"Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy","volume":"31","author":"Uy","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"2023072115504747600_bib34","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.3324\/haematol.2016.162909","article-title":"Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes","volume":"102","author":"Woo","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2023072115504747600_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/ejh.13390","article-title":"Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment","volume":"104","author":"Calleja","year":"2020","journal-title":"Eur J Haematol"},{"key":"2023072115504747600_bib36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"issue":"17","key":"2023072115504747600_bib37","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2023072115504747600_bib38","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"7739","key":"2023072115504747600_bib39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41586-018-0811-x","article-title":"Age-related remodelling of oesophageal epithelia by mutated cancer drivers","volume":"565","author":"Yokoyama","year":"2019","journal-title":"Nature"},{"issue":"2","key":"2023072115504747600_bib40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-022-03347-3","article-title":"Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial","volume":"116","author":"Miyazaki","year":"2022","journal-title":"Int J Hematol"},{"issue":"10","key":"2023072115504747600_bib41","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1101\/gad.1291305","article-title":"PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints","volume":"19","author":"Lu","year":"2005","journal-title":"Genes Dev"},{"issue":"26","key":"2023072115504747600_bib42","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023072115504747600_bib43","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"26","key":"2023072115504747600_bib44","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023072115504747600_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germline DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2023072115504747600_bib46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00277-012-1581-4","article-title":"Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine","volume":"92","author":"Breccia","year":"2013","journal-title":"Ann Hematol"},{"issue":"3","key":"2023072115504747600_bib47","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2023072115504747600_bib48","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"2023072115504747600_bib49","first-page":"797","article-title":"Decitabine in TP53-Mutated AML","volume":"376","author":"Welch","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023072115504747600_bib50","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"25","key":"2023072115504747600_bib51","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023072115504747600_bib52","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic Syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2023072115504747600_bib53","doi-asserted-by":"crossref","first-page":"15099","DOI":"10.1038\/ncomms15099","article-title":"Clonal evolution in myelodysplastic syndromes","volume":"8","author":"da Silva-Coelho","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"2023072115504747600_bib54","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2015-11-679167","article-title":"Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure","volume":"128","author":"Mossner","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023072115504747600_bib55","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","article-title":"Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia","volume":"32","author":"Rothenberg-Thurley","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"2023072115504747600_bib56","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"33","key":"2023072115504747600_bib57","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023072115504747600_bib58","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s00432-019-03016-9","article-title":"5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes","volume":"145","author":"Gawlitza","year":"2019","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"8","key":"2023072115504747600_bib59","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","article-title":"Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment","volume":"100","author":"Daskalakis","year":"2002","journal-title":"Blood"},{"issue":"13","key":"2023072115504747600_bib60","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2009-02-203547","article-title":"Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies","volume":"114","author":"Fandy","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2023072115504747600_bib61","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3624\/2065468\/blooda_adv-2022-009564-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3624\/2065468\/blooda_adv-2022-009564-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T16:02:38Z","timestamp":1689955358000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3624\/495133\/Postazacitidine-clone-size-predicts-long-term"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":61,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009564","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}